Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial

Leili Gao, Byung Wan Lee, Manoj Chawla, Joshua Kim, Li Huo, Liying Du, Yan Huang, Linong Ji

Research output: Contribution to journal › Article › peer-review

44 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science